Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company
Limited (TSE:4502) today announced that patients with Hodgkin lymphoma
(HL) who received ADCETRIS (brentuximab vedotin) as consolidation
therapy immediately following an autologous stem cell transplantation
(ASCT) lived significantly longer without disease progression compared
to patients who received placebo.
for Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma investment picks